NetworkNewsBreaks – Processa Pharmaceuticals Inc
Post# of 40
(Total Views: 193)
Posted On: 02/22/2021 2:26:03 PM
NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://nnw.fm/w856r. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://nnw.fm/w856r. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)